CompletedNCT00658567
Pimavanserin for psychosis in Parkinson’s disease
About this title
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Read the official source — NCT00658567Medication studyAges 40+Multiple countriesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: from 40 years.
- Listed locations
- La Habra and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 123
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Belgium, Austria, ...
- Age range
- Over 40 Years
- Official registry ID
- NCT00658567
- Official title
Show the full official title
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Get this study by email
Recruitment & locations
CompletedLa Habra, United States · Laguna Hills, United States · Reseda, United States
43 more locations
- Ventura, United States
- Englewood, United States
- Farmington, United States
- Deerfield Beach, United States
- Panama City, United States
- Sarasota, United States
- Boston, United States
- Worcester, United States
- Clinton, United States
- Detroit, United States
- East Lansing, United States
- Columbia, United States
- Omaha, United States
- Albany, United States
- Commack, United States
- Charlotte, United States
- Durham, United States
- New Bern, United States
- Toledo, United States
- Philadelphia, United States
- Houston, United States
- Burlington, United States
- Innsbruck, Austria
- Brussels, Belgium
- Ottignies, Belgium
- Roeselare, Belgium
- Chieti Scalo, Italy
- Grossetto, Italy
- Roma, Italy
- Bydgoszcz, Poland
- Katowice, Poland
- Lodz, Poland
- Lublin, Poland
- Coimbra, Portugal
- Lisbon, Portugal
- Porto, Portugal
- Belgrade, Serbia
- Barcelona, Spain
- Donostia / San Sebastian, Spain
- Santiago de Compostela, Spain
- Jönköping, Sweden
- Linköping, Sweden
- Stockholm, Sweden
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including Pimavanserin tartrate (ACP-103).
Who was this study for?
Listed age limits: from 40 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia